Search Result

Results for "

human hepatocellular liver carcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Aryl Hydrocarbon Receptor (1) Autophagy (1) Bcl-2 Family (1) BCL6 (4) Caspase (4) CDK (1) CTLA-4 (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (2) Drug Derivative (3) Drug Metabolite (1) Endogenous Metabolite (5) ERK (1) Ferroptosis (1) Glutathione S-transferase (1) Glycoprotein VI (1) HBV (1) HCV (1) HSP (1) Interleukin Related (5) JNK (1) MDM-2/p53 (1) MetAP (2) Microtubule/Tubulin (1) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) Parasite (1) PNPLA3 (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) STAT (4) TNF Receptor (1)
By Research Areas:	Cancer (15) Infection (5) Inflammation/Immunology (2) Metabolic Disease (5)

By Targets:

Apoptosis (5)

Aryl Hydrocarbon Receptor (1)

Autophagy (1)

Bcl-2 Family (1)

BCL6 (4)

Caspase (4)

CDK (1)

CTLA-4 (1)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (2)

Drug Derivative (3)

Drug Metabolite (1)

Endogenous Metabolite (5)

ERK (1)

Ferroptosis (1)

Glutathione S-transferase (1)

Glycoprotein VI (1)

HBV (1)

HCV (1)

HSP (1)

Interleukin Related (5)

JNK (1)

MDM-2/p53 (1)

MetAP (2)

Microtubule/Tubulin (1)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

Parasite (1)

PNPLA3 (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

STAT (4)

TNF Receptor (1)

By Research Areas:

Cancer (15)

Infection (5)

Inflammation/Immunology (2)

Metabolic Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2334

Glycochenodeoxycholic acid 5+ Cited Publications Chenodeoxycholylglycine	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N2334A

Glycochenodeoxycholic acid sodium salt 5+ Cited Publications Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-163959

PF-07853578	PNPLA3	Metabolic Disease Cancer
PF-07853578 is an orally active PNPLA3 modulator. PF-07853578 significantly reduces human PNPLA3-I148M protein levels and effectively decreases hepatic triglyceride content by reducing this mutant protein. PNPLA3 degrader-1 can be used in the research of liver cirrhosis and hepatocellular carcinoma .

HY-N2334AR

Glycochenodeoxycholic acid sodium salt (Standard) Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)	Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N2334R

Glycochenodeoxycholic acid (Standard) Chenodeoxycholylglycine (Standard)	Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].

HY-129247

Versicolorin A	MDM-2/p53 Aryl Hydrocarbon Receptor Cytochrome P450	Cancer
Versicolorin A is a biosynthetic precursor of Aflatoxin B1 (HY-N6615). Versicolorin A induces phosphorylation of p53. Versicolorin A activates the aryl hydrocarbon receptor AhR and significantly induces the expression of CYP1A1. Versicolorin A exerts genotoxic and cytotoxic effects. Versicolorin A enhances the genotoxicity of aflatoxin B1 in cells by promoting CYP450-mediated bioactivation of aflatoxin B1. Versicolorin A can be used in research related to colorectal cancer and hepatocellular carcinoma .

HY-N15577

Antiproliferative agent-69	Drug Derivative	Cancer
Antiproliferative agent-69 (Compound 1) is a prenylated kaempferol derivative found in the fresh bud’s fur of Platanus acerifolia. Antiproliferative agent-69 shows significant antiproliferative effects against human breast cancer cells (MCF-7) and human hepatocellular carcinoma cells (Hep-G2) with IC₅₀ values of 38.2 μM and 39.5 μM, respectively. Antiproliferative agent-69 is promising for research of breast cancer and liver cancer .

HY-P991566

KD6001	CTLA-4	Cancer
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC₅₀: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .

HY-N10207

Penicitide A	Endogenous Metabolite	Infection Cancer
Penicitide A is a marine secondary metabolite. Penicitide A shows moderate cytotoxicity against pathogen A. brassicae and the human hepatocellular liver carcinoma (HepG2) cell line .

HY-138813R

N-Desethyl Sunitinib hydrochloride (Standard) SU-12662 hydrochloride (Standard)	Reference Standards Drug Metabolite	Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N15535

Cuneataside E	Others	Cancer
Cuneataside E is a phenylpropanoid glycoside compound found in Lespedeza cuneata. Cuneataside E exhibits hepatoprotective activity against the toxicity induced by N-acetyl-p-aminophenol (APAP) in the human hepatocellular carcinoma cell line HepG2. Cuneataside E is promising for research of liver diseases .

HY-153547

HSP90-IN-21	Parasite	Infection Inflammation/Immunology
HSP90-IN-21 (5e) is an antiplasmodial agent, with IC₅₀ values of 0.04, 0.17 and 2.91 μM against erythrocytic stage of P. falciparum (Pf3D7 and PfDd2 strains), cytotoxicity of human liver hepatocellular carcinoma cell line (HepG2), respectively .

HY-N19127

Aspergillusidone E	Cytochrome P450	Cancer
Aspergillusidone E is an aromatase inhibitor with an aromatase IC₅₀ of 1.0 μM. Aspergillusidone E exhibits cytotoxicity against cancer cells. Aspergillusidone E can be used in research related to various cancers such as breast cancer and liver cancer .

HY-N16857

Didendronbiline A	Drug Derivative	Others
Didendronbiline A is a natural phenolic compound.

HY-181644

NS-181	MetAP	Infection
NS-181 is an orally active MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis .

HY-183716

Mito-TP-2	Drug Derivative	Cancer
Mito-TP-2 is a triptolide (HY-32735) derivative. Mito-TP-2 exhibits concentration-dependent cytotoxicity in cancer cells. Mito-TP-2 is selectively driven and accumulated into the mitochondria of tumor cells by mitochondrial transmembrane potential and exerts specific mitochondrial toxicity. Mito-TP-2 can be used for the research of liver cancer, breast cancer, and non-small cell lung cancer .

HY-181643

YOK24	MetAP	Infection
YOK24 is an orally active MetAP2 inhibitor and anti-amoebic agent. YOK24 binds covalently to MetAP2 and inhibits its peptidase activity, where MetAP2 is a protein essential for the proliferation of Entamoeba histolytica. YOK24 can be used in the research of amoebiasis .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

Cat. No.	Product Name

HY-L101

Anti-Liver Cancer Compound Library	2,879 compounds
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc. MCE offers a unique collection of 2,879 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Anti-Liver Cancer Compound Library

2,879 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,879 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area